MILPITAS, Calif. - Zepp Health Corporation (NYSE: ZEPP), in collaboration with Wild.AI, has announced the integration of a women’s health and wellness app on its Amazfit Active series smartwatches. This partnership introduces Wild.AI's app directly onto the smartwatches, marking the first time such technology is available on the Amazfit Active series, with plans to extend the feature to other series.
The Wild.AI app offers personalized health insights and recommendations based on over 450 whitepapers, focusing on women's hormonal and menstrual cycles. The app provides tailored training plans and diet suggestions to support women’s health needs during various life stages, including reproductive years and menopause.
The integration allows users to manage their health directly from their wrist, providing a convenient and seamless experience. Women can track their menstrual cycle, various types of birth control, and receive advice on diet and exercise tailored to their physiology.
Zepp Health's CEO, Wayne Huang, emphasized the company's dedication to advancing smartwatch technology to cater to women's health needs. Hélène Guillaume, founder and CEO of Wild.AI, highlighted the significance of making the Wild.AI experience accessible outside the mobile app for the first time, aiming to redefine how women interact with fitness and well-being technology.
The Amazfit Active smartwatch, designed for an active lifestyle, features an ultra-large 1.75" AMOLED display and a battery life of up to two weeks. It incorporates Zepp Flow™ for AI-powered comprehensive assistance, including voice control capabilities.
Currently, the Wild.AI mini app supports English and is available to Amazfit Active users in the US. It is expected to be available to users in Europe and the Asia-Pacific region on September 1st, 2024.
The announcement reflects Zepp Health's commitment to providing health insights and tools that empower women, addressing the historical gap in female-focused medical research and technology. This initiative is based on a press release statement from Zepp Health.
In other recent news, Zepp Health Corporation reported a strong first-quarter performance for 2024, with a focus on growth and profitability. The company's self-branded products, which account for over 85% of total revenue, have been a significant driver of this success. The gross margin reached a historical high of 37%, marking a significant achievement for the company. Despite a seasonal decline in sales, Zepp Health's financial outlook remains positive, with an expected Q2 revenue of between $40 million and $55 million.
In addition to the financial highlights, Zepp Health is addressing a non-compliance notice from the U.S. main Board and is committed to maintaining its listing status. New product launches like the Helio Ring are also on the horizon, with the company expecting these initiatives to drive further margin expansion. The company's strategic initiatives also include marketing campaigns leading up to significant events such as the EuroCup and Summer Olympics.
While the company reported a loss in operating results for Q1, it has achieved positive operating cash flow for the seventh consecutive quarter. This indicates a solid financial performance, with the company's management team expressing confidence in its strategic direction and sustained profitability. The recent developments at Zepp Health underline the company's commitment to growth and innovation, with a strong emphasis on its self-branded products.
InvestingPro Insights
In the wake of Zepp Health Corporation's (NYSE: ZEPP) announcement regarding the integration of Wild.AI's women's health app on its Amazfit Active series smartwatches, the company's financial metrics provide a mixed picture. Zepp Health is currently trading at a low Price / Book multiple of 0.13, indicating that the market may be undervaluing the company's assets relative to its share price. Additionally, the stock has seen a significant return over the last week, with a 29.65% increase in price total return.
On the other hand, analysts are cautious about the company's short-term prospects. They anticipate a sales decline in the current year, and do not expect the company to be profitable this year. Zepp Health's revenue has also decreased by 46.98% over the last twelve months as of Q1 2024, which could be a point of concern for investors. The company's operating income margin for the same period stands at -7.95%, further emphasizing the challenges it faces in achieving profitability.
For investors interested in deeper analysis, there are additional InvestingPro Tips available that could provide more insights into Zepp Health's performance and potential. These tips can be accessed through the InvestingPro platform at https://www.investing.com/pro/ZEPP, where investors can find a total of 13 tips to help them make more informed decisions.
Zepp Health's partnership with Wild.AI could be a strategic move to differentiate its products in a competitive market. The company's focus on women's health needs, a historically underserved area, may resonate with consumers and potentially contribute to its long-term growth. However, investors would be wise to consider the company's financial health and market performance as part of their overall assessment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.